Marshall Wace LLP Raises Position in Zoetis Inc. (NYSE:ZTS)

Marshall Wace LLP grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 7,608.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 835,684 shares of the company’s stock after buying an additional 824,843 shares during the quarter. Marshall Wace LLP owned 0.18% of Zoetis worth $144,874,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in ZTS. Resources Management Corp CT ADV boosted its stake in Zoetis by 7.9% during the 2nd quarter. Resources Management Corp CT ADV now owns 14,313 shares of the company’s stock valued at $2,481,000 after purchasing an additional 1,049 shares during the last quarter. Bank of Montreal Can lifted its holdings in shares of Zoetis by 0.3% during the second quarter. Bank of Montreal Can now owns 1,121,131 shares of the company’s stock valued at $192,212,000 after purchasing an additional 3,637 shares in the last quarter. Lombard Odier Asset Management Europe Ltd purchased a new stake in shares of Zoetis during the second quarter valued at $3,560,000. Public Sector Pension Investment Board increased its holdings in Zoetis by 69.1% in the 2nd quarter. Public Sector Pension Investment Board now owns 17,281 shares of the company’s stock worth $2,996,000 after buying an additional 7,061 shares in the last quarter. Finally, Steel Grove Capital Advisors LLC boosted its holdings in shares of Zoetis by 37.2% during the 2nd quarter. Steel Grove Capital Advisors LLC now owns 1,734 shares of the company’s stock valued at $301,000 after acquiring an additional 470 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Stifel Nicolaus increased their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. BTIG Research upped their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Piper Sandler raised their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $220.38.

Zoetis Trading Up 0.5 %

ZTS stock opened at $193.59 on Tuesday. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The business has a 50 day simple moving average of $185.01 and a two-hundred day simple moving average of $174.42. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The company has a market capitalization of $88.33 billion, a price-to-earnings ratio of 37.30, a PEG ratio of 2.98 and a beta of 0.88.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter in the previous year, the company earned $1.41 EPS. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. Research analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.